Five Swiss startups have announced leadership changes. Healthtech companies Docjo and MindMaze have named new CEOs, as has Zurich-based AI company Squirro. Flux Mobility has hired a new CTO, while Santhera Pharmaceuticals has appointed a new CCO following the retirement of its previous one.
Docjo, founded in 2023, has developed a platform for continuous digital communication between patients and healthcare professionals, with a focus on chronic disease management. The company has appointed Roger Pierenkemper as CEO, succeeding Oliver Felix, as it moves into a new phase centred on go-to-market strategy and scaling. Pierenkemper brings leadership experience from MedTech and regulated technology environments, with a track record in organisational scaling, financing and M&A.
New CEO joins Squirro
Zurich-based Squirro, which provides enterprise AI to banks, governments, telecommunication companies and manufacturers, has appointed David Clarke as Chief Executive Officer. Clarke succeeds Dr Dorian Selz, who moves to the role of Executive Deputy Chairman. Clarke brings over 30 years of experience in the information industry, with expertise in knowledge graphs, enterprise AI and large-scale deployments.
MindMaze appoints CEO
MindMaze Therapeutics has appointed Zach Henderson as Chief Executive Officer. The company develops neurological platform-based digital treatments targeting stroke, Parkinson’s disease and other brain disorders and went public in December 2025.. Henderson brings over 30 years of experience in healthcare technology, with a track record in scaling platforms and driving recurring revenue growth.
Flux Mobility hires new CTO
Electric commercial vehicle maker Flux Mobility has welcomed Christian Korte as Chief Technology Officer. The company develops vehicles based on a flexible platform concept designed to convert conventional fleets to electric. Flux Mobility’s customers include several of the largest municipal companies in Switzerland and Germany. Korte said his focus will be on scaling and certifying what has already been built, and expanding the technology side of the business.
Santhera Pharmaceuticals brings in new CCO
Santhera Pharmaceuticals, which develops therapies for rare neuromuscular and pulmonary diseases, has appointed Marc Clausse as Chief Commercial Officer, effective 1 June 2026. He succeeds Geert Jan van Daal, who retires after 11 years with Santhera and will remain available to support the transition. Clausse brings over 25 years of international life sciences experience spanning specialty, oncology and rare diseases, with a particular focus on European market access and strategic partner management.
(Press release/AJ)
